Browse > Article
http://dx.doi.org/10.5045/br.2018.53.4.320

Altered expression of MALAT1 lncRNA in chronic lymphocytic leukemia patients, correlation with cytogenetic findings  

Ahmadi, Abdolrahim (Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University)
Kaviani, Saeid (Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University)
Yaghmaie, Marjan (Hematology-Oncology and Stem Cell Transplantation Research Center)
Pashaiefar, Hossein (Hematology-Oncology and Stem Cell Transplantation Research Center)
Ahmadvand, Mohammad (Hematology-Oncology and Stem Cell Transplantation Research Center)
Jalili, Mahdi (Hematology-Oncology and Stem Cell Transplantation Research Center)
Alimoghaddam, Kamran (Hematology-Oncology and Stem Cell Transplantation Research Center)
Eslamijouybari, Mohammad (Comprehensive Cancer Research Center, Mazandaran University of Medical Science)
Ghavamzadeh, Ardeshir (Hematology-Oncology and Stem Cell Transplantation Research Center)
Publication Information
BLOOD RESEARCH / v.53, no.4, 2018 , pp. 320-324 More about this Journal
Abstract
Background Recent studies have devoted much attention to non-protein-coding transcripts in relation to a wide range of malignancies. MALAT1, a long non-coding RNA, has been reported to be associated with cancer progression and prognosis. Thus, we here determined MALAT1 gene expression in chronic lymphocytic leukemia (CLL), a genetically heterogeneous disease, and explored its possible relationships with cytogenetic abnormalities. Methods MALAT1 expression level was evaluated using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) on blood mononuclear cells from 30 non-treated CLL patients and 30 matched healthy controls. Cytogenetic abnormalities were determined in patients by fluorescence in situ hybridization (FISH). Results MALAT1 expression level was up-regulated in the CLL group compared to healthy controls (P=0.008). Del13q14, followed by Del11q22, were the most prevalent cytogenetic abnormalities. We found no association between the FISH results and MALAT1 expression in patients. Conclusion Altered expression of MALAT1 is associated with CLL development. Further investigations are required to assess the relationship between this long non-coding RNA and CLL patient survival and prognosis.
Keywords
MALAT1; Chronic lymphocytic leukemia; qRT-PCR; FISH;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kim SH, Kim SH, Yang WI, Kim SJ, Yoon SO. Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma. Oncotarget 2017;8:31305-17.
2 Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013;27:173-206.   DOI
3 Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012;11:CD008079.
4 Charbotel B, Fervers B, Droz JP. Occupational exposures in rare cancers: A critical review of the literature. Crit Rev Oncol Hematol 2014;90:99-134.   DOI
5 Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discov Med 2011;11:115-23.
6 Inamura K. Major tumor suppressor and oncogenic non-coding RNAs: clinical relevance in lung cancer. Cells 2017;6:E12.   DOI
7 Taheri M, Habibi M, Noroozi R, et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene 2017;613:20-4.   DOI
8 Tripathi V, Shen Z, Chakraborty A, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013;9:e1003368.   DOI
9 Ahmadi J, Kaviani Gebelli S, Atashi A. Evaluation of MALAT1 gene expression in AML and ALL cell lines. Faslnamahi Kumish 2015;17:179-86.
10 Cho SF, Chang YC, Chang CS, et al. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer 2014;14:809.   DOI
11 Janbabaei G, Hedayatizadeh-Omran A, Alizadeh-Navaei R, et al. An epidemiological study of patients with breast cancer in Northern Iran, between 2006 and 2015. WCRJ 2016;3:e803.
12 Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics 2017;15:177-86.   DOI
13 Li J, Xuan Z, Liu C. Long non-coding RNAs and complex human diseases. Int J Mol Sci 2013;14:18790-808.   DOI
14 Eftekharian MM, Ghafouri-Fard S, Soudyab M, et al. Expression analysis of long non-coding RNAs in the blood of multiple sclerosis patients. J Mol Neurosci 2017;63:333-41.   DOI
15 Rahimi H, Sadeghian MH, Keramati MR, et al. Cytogenetic abnormalities with interphase FISH method and clinical manifestation in chronic lymphocytic leukemia patients in North-East of Iran. Int J Hematol Oncol Stem Cell Res 2017;11:217-24.
16 Balatti V, Pekarky Y, Rizzotto L, Croce CM. miR deregulation in CLL. Adv Exp Med Biol 2013;792:309-25.
17 Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 2015;125:407-10.   DOI
18 Sadighi S, Jahanzad I, Ali Mohagheghi M, et al. Somatic mutation in immunoglobulin gene variable region in patients with chronic lymphoid leukemia and its influence on disease prognosis. Middle East J Rehabil Health Stud 2016;2:e35848.
19 Ronchetti D, Manzoni M, Agnelli L, et al. lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer J 2016;6:e468.   DOI
20 Amodio N, Stamato MA, Juli G, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia 2018;32:1948-57.   DOI
21 Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90.
22 Zent CS. Time to test CLL p53 function. Blood 2010;115:4154-5.   DOI
23 Kay NE, Suen R, Ranheim E, Peterson LC. Confirmation of Rb gene defects in B-CLL clones and evidence for variable predominance of the Rb defective cells within the CLL clone. Br J Haematol 1993;84:257-64.   DOI
24 Huang JL, Liu W, Tian LH, et al. Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. Oncol Rep 2017;38:1353-62.   DOI
25 Isin M, Ozgur E, Cetin G, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta 2014;431:255-9.   DOI
26 Yoon JH, Kim Y, Yahng SA, et al. Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence. Hematol Oncol 2014;32:169-77.   DOI
27 Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med 2016;14:346.   DOI
28 Li LJ, Chai Y, Guo XJ, Chu SL, Zhang LS. The effects of the long non-coding RNA MALAT-1 regulated autophagy-related signaling pathway on chemotherapy resistance in diffuse large B-cell lymphoma. Biomed Pharmacother 2017;89:939-48.   DOI
29 Kokhaee P. B-cell chronic lymphocyte leukemia (B-CLL). Faslnamahi Kumish 2007;9:1-12.